Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Mathurin Fuméry, Jérôme Filippi, Véred Abitbol, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 7, pp. 944-951
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
María T. Abreu, David Rowbotham, Silvio Danese, et al.
Journal of Crohn s and Colitis (2022) Vol. 16, Iss. 8, pp. 1222-1234
Open Access | Times Cited: 80
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
Francesca Ferretti, Rosanna Cannatelli, Maria Camilla Monico, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2302-2302
Open Access | Times Cited: 65
Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis
Carlos Taxonera, David Olivares, Olga N. López‐García, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 6, pp. 610-619
Closed Access | Times Cited: 25
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 11, pp. 1312-1334
Open Access | Times Cited: 15
Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
Joel Thunberg, Olle Björkqvist, Charlotte Hedin, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 7, pp. 631-639
Open Access | Times Cited: 35
Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review
Javier P. Gisbert, Elizabeth Parody-Rúa, María Chaparro
Inflammatory Bowel Diseases (2023)
Open Access | Times Cited: 20
Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Shlomi Cohen, Helena Rolandsdotter, Kaija-Leena Kolho, et al.
Pediatric Drugs (2024) Vol. 26, Iss. 5, pp. 609-617
Open Access | Times Cited: 7
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
Antonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 101-109
Closed Access | Times Cited: 6
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent
Mathurin Fuméry, Mélanie Serrero, Guillaume Bouguen, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 10, pp. 1615-1621
Closed Access | Times Cited: 6
Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis
Hu Zhang, Chenlu Mu, Yu Jeffrey Gu, et al.
Pharmacological Research (2024) Vol. 202, pp. 107108-107108
Open Access | Times Cited: 5
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis
Dahham Alsoud, Gert De Hertogh, Griet Compernolle, et al.
Journal of Crohn s and Colitis (2022) Vol. 16, Iss. 10, pp. 1562-1570
Closed Access | Times Cited: 20
Research Advances of Ustekinumab in the Treatment of Ulcerative Colitis
明聪 袁
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 523-529
Closed Access
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study
Sailish Honap, Lulia Al‐Hillawi, Samantha Baillie, et al.
Frontline Gastroenterology (2022) Vol. 13, Iss. 6, pp. 517-523
Open Access | Times Cited: 16
Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases
Parambir S. Dulai, Siddharth Singh, Vipul Jairath, et al.
Gastroenterology (2023) Vol. 166, Iss. 3, pp. 396-408.e2
Open Access | Times Cited: 10
Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
Giammarco Mocci, Antonio Tursi, F M Onidi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1519-1519
Open Access | Times Cited: 3
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium
Andrés Yarur, Ryan C. Ungaro, Katherine Huang, et al.
Inflammatory Bowel Diseases (2024) Vol. 31, Iss. 1, pp. 131-139
Closed Access | Times Cited: 3
Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study
Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Matheus Freitas Cardoso de Azevedo, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 3
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
Antoine Meyer, Mathurin Fuméry, Laurent Peyrin‐Biroulet, et al.
Scandinavian Journal of Gastroenterology (2022) Vol. 57, Iss. 12, pp. 1454-1462
Closed Access | Times Cited: 14
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
Daniela Pugliese, Giuseppe Privitera, Marcello Fiorani, et al.
Therapeutic Advances in Gastroenterology (2022) Vol. 15
Open Access | Times Cited: 13
The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review
Humza Awan, Urooj Fatima, Ryan Eaw, et al.
Cureus (2023)
Open Access | Times Cited: 7
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort
Marisa Iborra, R Ferreiro-Iglesias, Martín-Arranz Maria Dolores, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 59, Iss. 3, pp. 260-268
Closed Access | Times Cited: 7
Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
Giammarco Mocci, Antonio Tursi, F M Onidi, et al.
(2024)
Open Access | Times Cited: 2
Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study
Katsuyoshi Ando, Mikihiro Fujiya, Nobuhiro Ueno, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 2
Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries
He Zhou, Fang Wang, Jian Wan, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1894-1894
Open Access | Times Cited: 6
Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
Brian Bressler, Jennifer Jones, Tracy S. H. In, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4421-4439
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top